ClinicalTrials.gg
RecruitingNCT06540833Updated Nov 3, 2026

A Study to Assess the Efficacy and Safety of ITI-1284 in the Treatment of Psychosis Associated With Alzheimer's Disease

A Phase 2 interventional study of ITI-1284 and Placebo in Psychotic Disorders and Alzheimer Disease, sponsored by Intra-Cellular Therapies, Inc.. Recruiting at 71 sites in 10 countries. Open to participants aged 55 Years and older. Per ClinicalTrials.gov, last updated 2026-11-03.

Sponsored by Intra-Cellular Therapies, Inc. (part of Johnson & Johnson) · Phase 2, Interventional, and Treatment

From the registry’s dates

  • Started Aug 2024; still recruiting 2 years 3 months later.
Updated Nov 3, 2026Site recruiting status changed4 sites addedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
370
Allocation
Randomized
Ages
55 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 58 studies in Psychotic Disorders by Johnson & Johnson — 1 open to participants now, 1 under way, none of them phase 3. Psychotic Disorders · Johnson & Johnson.

Planned enrollment
14th of 49
370 · median 225
Started
2024
the only one that year
Phase 2
2 of 58
1 open now
Registered
58th of 58
by date

Among the 58 studies in Psychotic Disorders by Johnson & Johnson, this one is the 14th largest by planned enrollment of the 49 interventional ones that give a count, is the only one that started in 2024, is one of 2 in phase 2, and was the 58th registered.

Psychotic Disorders

1,589 studies on the registry are indexed under Psychotic Disorders; 281 are open to participants now.

Browse Psychotic Disorders studies →

Open to participants now

1 of the 58 studies in Psychotic Disorders by Johnson & Johnson is open now, in 10 countries.

By country, each count listing its studies:

Who these studies take

Of the 204 Psychotic Disorders studies recruiting now, 53 (26%) set no upper age limit and 142 (70%) stop at 75 or younger; 50 take children under 18; 41 take healthy volunteers.

This study: 55 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 58 studies in Psychotic Disorders by Johnson & Johnson, or all of them as a file.
02

Study summary

This is a multicenter, randomized, double-blind, parallel-group, placebo-controlled, flexible-dose study evaluating the efficacy, safety, and tolerability of ITI-1284 compared with placebo in the treatment of psychosis in patients with AD.

03

Conditions studied

  • Psychotic Disorders
  • Alzheimer Disease
04

Who can participate

Ages eligible
55 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Can understand the nature of the trial and protocol requirements and provide signed , if in the judgement of the Investigator is deemed competent to provide consent or if patient is deemed not competent to provide informed consent, with the patient's assent (if capable), consent may be provided by an appropriate person (eg, patient's Legally Authorized Representative [LAR]) before the initiation of any study-specific procedures in accordance with local regulations
  2. Meets clinical criteria for AD based on 2011 NIA-AA criteria and either:

    1. Has a high likelihood for amyloid pathology consistent with AD, as confirmed by blood-based biomarker at Screening as detected by an appropriately validated test; or
    2. Has documented confirmation of AD by cerebrospinal fluid (CSF) biomarker or amyloid positron emission tomography (PET) brain scan
  3. Meets criteria for psychosis in accordance with the International Psychogeriatric Association (IPA) provisional consensus definition at Screening and Baseline
  4. Scoring ≥ 2 on any item of the BEHAVE-AD Part A. Paranoid and Delusional Ideation item and/or Part B. Hallucinations item (ie, psychosis subscale) at Screening and Baseline
  5. CGI-S score ≥ 4 at Screening and Baseline
  6. , 2nd Edition™: Standard Version (MMSE-2®:SV) score of 6 to 24 (inclusive) at Screening with sufficient verbal ability to understand and answer questions and comply with procedures
  7. Has a designated caregiver (eg, relative, housemate, close personal friend, or professional caregiver)

Exclusion criteria

Exclusion Criteria:

  1. Psychotic symptoms that are primarily attributable to delirium, substance abuse, or another general-medical condition (for example, hypothyroidism) or has been diagnosed with one or more of the following psychiatric conditions:

    1. Schizophrenia, schizoaffective disorder, or other psychotic disorder that is not related to Alzheimer's dementia
    2. Bipolar disorder
  2. Risk for suicidal behavior during the course of their participation in the study or is considered to be an imminent danger to themselves or others, in the opinion of the investigator, and/or as assessed by C-SSRS; or the patient has had 1 or more suicide attempts within 2 years prior to Screening
  3. The patient is unable or unwilling to discontinue other drugs with known psychotropic properties or any non-psychotropic drugs with known or potentially significant central nervous system effects, as reviewed by the Sponsor or designee
  4. The patient is hospitalized or receiving skilled nursing care for any medical condition other than dementia
  5. The patient is bedridden or has any significant medical condition that is unstable and would either:

    1. Place the patient at undue risk from study drug or undergoing study procedures; or
    2. Interfere with the interpretation of safety or efficacy evaluations performed during the course of the study
  6. The patient is in hospice or end-of-life care
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

MMSE and MoCA

Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
370 participants (estimated)

Study arms

  • Experimental
    ITI-1284

    Drug: ITI-1284

  • Placebo comparator
    Placebo

    Drug: Placebo

Interventions

  • ITI-1284 10 mg or 20 mg rapidly disintegrating tablet, taken once daily, sublingual administration

  • DrugPlacebo

    Placebo rapidly disintegrating tablet, taken once daily, sublingual administration

06

What researchers measure

Primary outcomes

  1. BEHAVE-AD psychosis subscale score

    The BEHAVE-AD psychosis subscale is comprised of 7 items from the paranoid and delusional ideations domain and 5 items from the hallucinations domain. The scale is rated on a 4--point scale of severity, from 0 (not present) to 3 (present, generally with an emotional and physical component). The maximum score for the psychosis subscale is 36.

    Time frame: Week 6

Secondary outcomes

  1. CGI-S score

    The CGI-S is a clinician-rated scale to assess a patient's overall mental health. The scale ranges from 1 (normal, not at all ill) to 7 (among the most extremely ill patients)

    Time frame: Week 6

07

Study locations

48 of 71 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Aug 2024 (actual). Primary completion is estimated for Sep 2028, 49 months after the start.

Of 39 phase 2 interventional studies under Psychotic Disorders, half reached primary completion within 39 months of starting (the median), counting those still running; a quarter within 22 and three quarters within 53. This study's planned 49 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 2, 2024
First posted
Aug 6, 2024
StartActual
Aug 15, 2024
Primary completionEst.
Sep 30, 2028
CompletionEst.
Dec 29, 2028
Last update
Nov 3, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
4 sites added. 7 sites changed recruiting status (3 now recruiting, 3 now completed, …)
Show 7 sites
  • Wellness Research Center · Miami, United StatesSuspended→Recruiting
  • Sunshine Medical Solution · Miami, United StatesSuspended→Recruiting
  • University of Texas Health Science Center at San Antonio · San Antonio, United StatesRecruiting→Completed
  • Medical Center Sv Dimitar Blagoevgrad · Blagoevgrad, BulgariaRecruiting→Completed
  • Ambulatory for Individual Practice for Specialized Medical Care in Psychiatry Dr. Ivo Natsov ET · Cherven Bryag, BulgariaSuspended→Recruiting
  • Centrul de Evaluarea si Tratament al Toxicodependentelor pentru Tineri Sf. Stelian · Bucharest, RomaniaSuspended→Completed
  • Special Hospital for Psychiatric Diseases Sveti Vracevi · Novi Kneževac, SerbiaRecruiting→Suspended
Show 4 added (3 Italy, 1 United States)
  • AMC Research, LLC · Matthews, United States
  • Fondazione Istituto G. Giglio · Cefalù, Italy
  • Ospedale di Arzignano · Arzignano, Italy
  • Ospedale Cardinale G. Panico · Tricase, Italy
across 2 updates, Sep 29, 2026 – Nov 3, 2026
Show all 2 updates
  1. Nov 3, 2026
    2 sites added. 8 sites changed recruiting status (4 now recruiting, 3 now completed, …)
    Show 8 sites
    • Wellness Research Center · Miami, United StatesSuspended→Recruiting
    • Sunshine Medical Solution · Miami, United StatesSuspended→Recruiting
    • University of Texas Health Science Center at San Antonio · San Antonio, United StatesRecruiting→Completed
    • Medical Center Sv Dimitar Blagoevgrad · Blagoevgrad, BulgariaRecruiting→Completed
    • Ambulatory for Individual Practice for Specialized Medical Care in Psychiatry Dr. Ivo Natsov ET · Cherven Bryag, BulgariaSuspended→Recruiting
    • Medical Center Hera EOOD · Sofia, BulgariaSuspended→Recruiting
    • Centrul de Evaluarea si Tratament al Toxicodependentelor pentru Tineri Sf. Stelian · Bucharest, RomaniaSuspended→Completed
    • Special Hospital for Psychiatric Diseases Sveti Vracevi · Novi Kneževac, SerbiaRecruiting→Suspended
    Show 2 added (2 Italy)
    • Ospedale di Arzignano · Arzignano, Italy
    • Ospedale Cardinale G. Panico · Tricase, Italy
    + 1 other change: verification date
  2. Sep 29, 2026
    2 sites added. Medical Center Hera EOOD is now Suspended
    Show 2 added (1 United States, 1 Italy)
    • AMC Research, LLC · Matthews, United States
    • Fondazione Istituto G. Giglio · Cefalù, Italy
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06540833
Responsible party
Sponsor
First posted
Aug 6, 2024
Start date
Aug 15, 2024
Primary completion
Sep 30, 2028 (estimated)
Completion
Dec 29, 2028 (estimated)
Last update
Nov 3, 2026

Study contacts

Study Contact
Contact
Participate-In-This-Study1@its.jnj.com
844-434-4210
Intra-Cellular Therapies, Inc. Clinical Trial
study director · Intra-Cellular Therapies, Inc.

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Deulumateperone

Start the discussion